Understanding How To Develop BTK Inhibitors In MS Is Evolving

Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.

Microglia cells
Microglia immune cells in the brain • Source: Shutterstock (Shutterstock)

The failure of Merck KGaAs Phase III trials of the BTK inhibitor evobrutinib in multiple sclerosis (MS) raises several questions about the use of this class of compounds to treat the disease. Safety has long been a concern for these molecules: at various times, MS trials of evobrutinib, Sanofi’s tolebrutinib and, most recently, Roche Holding AG’s fenebrutinib have, to some degree, been placed on clinical hold by FDA. Also see "Clinical Hold For Merck KGaA’s BTK Inhibitor Evobrutinib For MS Raises Class Safety Fears" - Scrip, 12 April, 2023. Also see "Sanofi’s MS Candidate Tolebrutinib On Clinical Hold Following Liver Toxicities" - Scrip, 30 June, 2022. New drugs have emerged as compelling treatments for relapsing MS, making the design of late-stage clinical trials increasingly challenging. Similarly, the sweet spot for proving the value of new MS drugs is shifting towards progressive forms of the disease and a focus on treating disability with high-potency drugs, not preventing relapses.

Merck announced the results of its two pivotal EVOLUTION studies of evobrutinib on 6 December, 2023. Neither met the primary...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By 

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

MitoRx’s Muscle-Preserving Obesity Drug Takes Aim At GLP-1 Limitations

 
• By 

UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By 

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By 

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By 

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.